SEC Form S-8 filed by Bausch + Lomb Corporation

$BLCO
Ophthalmic Goods
Health Care
Get the next $BLCO alert in real time by email

Weekly insight reads limit reached.

Join Quantisnow to enjoy unlimited reads, alerts, live feeds, and more.

Meet Quantisnow

Stock alerts. Live news feeds. Press releases. Insider trading. FDA approvals & more.

Invest smarter

A better trading workflow

Access market-moving news before they break out to the general public. Let Quantisnow cut out the noise and only receive insights that matter.

Live feeds
Real-time news feeds for Press Releases, SEC Filings, FDA approvals, market insights and more.
Custom filters
Filter out the noise with company filters, market cap filters, price filters and more.
Audio Squawk
Multitask with confidence and let Quantsinow read breaking news out loud.
Product screenshot
Quantisnow AI Features

Save time

Unlock Insights with AI

Get quick summaries and precise Q&A for every insight, empowering you to make informed decisions without sifting through entire press releases and lengthy SEC filings.

Get alerted immediately

All your stock market alerts in one place

Quantisnow alerts are fast, customizable, and versatile.

Email alerts
Subscribe to your favorite stocks and receive email alerts each time a news pops up.
App notifications
Reduce alerting latency with in-app notifications. Same as email alerts, but faster.
Webhooks
Integrate with Quantisnow programmatically and receive live insights via webhooks
Granular alerts
Want to receive Press Releases but no SEC filings? No problem - Quantisnow alerts are highly customizable and can seemlessly tailor to your trading needs.

Elevate your trading.
Start using Quantisnow today.

Never miss an update.

App screenshot

Simple no-tricks pricing

One membership with full access and no delays.

Quantisnow Plus

Your personal trading assistant for just $39/month.

What's included

  • Live feeds
  • Audio squawk
  • Compact mode in feeds
  • Email alerts
  • App push alerts
  • Unlimited insights reads
  • Unlimited subscriptions
  • Advanced filters in live feeds
  • Support
  • No ads
  • AI-generated summaries and Q&A

One membership - all access

$39/month

Get access

$39/month with yearly billing, $49/month with monthly billing

News insights ingested and delivered in real time
5 million+
Real-time news alerts sent out to Quantisnow users
700,000+
Latency of news delivery pipelines to users via mobile app, webhooks, and email
<100ms
Get the next $BLCO alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$BLCO

DatePrice TargetRatingAnalyst
3/28/2025$24.00 → $15.00Overweight → Equal Weight
Wells Fargo
12/11/2024$24.00 → $22.00Buy → Neutral
Citigroup
12/2/2024$19.00Overweight → Equal-Weight
Morgan Stanley
10/15/2024$19.00 → $25.00In-line → Outperform
Evercore ISI
7/10/2024$19.00Outperform
Raymond James
5/6/2024$16.00 → $18.00Equal-Weight → Overweight
Morgan Stanley
1/4/2024$19.00 → $17.00Outperform → In-line
Evercore ISI
12/12/2023$16.00Hold
Stifel
More analyst ratings

$BLCO
Press Releases

Fastest customizable press release news feed in the world

See more
  • Bausch + Lomb Announces Voluntary Recall of enVista Aspire™, enVista Envy™ and Certain enVista® Monofocal Intraocular Lenses

    Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced a voluntary recall of intraocular lenses (IOLs) on its enVista platform. This action was taken out of an abundance of caution after the company received reports of complications, the cause of which could not immediately be explained. "As much as we believe in the enVista platform, patient safety will always be our number one priority," said Brent Saunders, chairman and CEO, Bausch + Lomb. "Surgeons and patients trust Bausch + Lomb, and I believe that this voluntary recall is the best thing we can do to honor that trust." The recall is in res

    $BLCO
    Ophthalmic Goods
    Health Care
  • Bausch + Lomb Will Release First-Quarter 2025 Financial Results on April 30

    Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its first-quarter financial results on Wednesday, April 30, 2025. Bausch + Lomb will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of the call. Conference Call Details Date:     Wednesday, April 30, 2025   Time:     8 a.m. ET   Webcast:     https://www.webcaster4.com/Webcast/Page/2883/51713   Participant Event Dial-in:     +

    $BLCO
    Ophthalmic Goods
    Health Care
  • Bausch + Lomb Launches Arise™ Orthokeratology Lens System in the United States

    Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of Arise, a lens fitting system that uses intelligent, cloud-based technology to streamline the orthokeratology lens design process. Arise seamlessly syncs directly with topographers – diagnostic tools that capture 3-D images of the eye – to create precise lens designs in seconds to treat myopia. These lenses include the first orthokeratology lens design with toric peripheral curves* approved by the U.S. Food and Drug Administration to treat myopia overnight. Myopia, or nearsightedness, is one of the most common ocular disorde

    $BLCO
    Ophthalmic Goods
    Health Care

$BLCO
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$BLCO
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$BLCO
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$BLCO
SEC Filings

See more

$BLCO
Leadership Updates

Live Leadership Updates

See more
  • Bausch + Lomb Announces Appointment of Karen L. Ling to Board of Directors

    Richard De Schutter to Retire from Board Following 2024 Annual Meeting Bausch + Lomb Corporation (TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Karen L. Ling has been appointed to its Board of Directors (the "Board"), effective immediately. Current director Richard De Schutter will retire from the Board effective as of the company's 2024 Annual Meeting of Shareholders (the "Annual Meeting"). With Ms. Ling's appointment, the Board has been temporarily expanded to 11 members and is expected to revert to 10 directors following the Annual Meeting. "Since my return to the company, Richard has been a trusted advisor,

    $BLCO
    Ophthalmic Goods
    Health Care
  • Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO

    Papa will lead Emergent into a new era of focusing on protecting public health, returning to growth and paying down the company's debt GAITHERSBURG, Md., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS), a global company providing solutions that address public health threats and delivering life-extending products to market, today announced that its Board of Directors has appointed Joseph C. Papa as president and CEO, effective February 21, 2024. Mr. Papa succeeds Haywood Miller, who will step down from his role as interim CEO, effective February 21, 2024. "Following a thorough search process, we are pleased to appoint Joe Papa as president and CEO of Emergent," sai

    $BLCO
    $EBS
    Ophthalmic Goods
    Health Care
    Biotechnology: Pharmaceutical Preparations
  • Bausch + Lomb Appoints Bob Bailey as Executive Vice President and Chief Legal Officer and Andrew Stewart as President, Ophthalmic Pharmaceuticals

    Mr. Bailey and Mr. Stewart Will Join Bausch + Lomb on April 24, 2023 Bausch + Lomb Corporation (TSX:BLCO) ("Bausch + Lomb" or the "Company"), a leading global eye health company dedicated to helping people see better to live better, announced the appointments of Bob Bailey as executive vice president (EVP) and Chief Legal Officer and Andrew Stewart as president, Ophthalmic Pharmaceuticals, effective April 24, 2023. Both Mr. Bailey and Mr. Stewart will join the executive management team of the Company. Concurrent with these appointments, Christina Ackermann will step down from her role as EVP, General Counsel and president, Ophthalmic Pharmaceuticals, and will leave Bausch + Lomb on April

    $BLCO
    Ophthalmic Goods
    Health Care

$BLCO
Financials

Live finance-specific insights

See more
  • Bausch + Lomb Will Release First-Quarter 2025 Financial Results on April 30

    Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its first-quarter financial results on Wednesday, April 30, 2025. Bausch + Lomb will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of the call. Conference Call Details Date:     Wednesday, April 30, 2025   Time:     8 a.m. ET   Webcast:     https://www.webcaster4.com/Webcast/Page/2883/51713   Participant Event Dial-in:     +

    $BLCO
    Ophthalmic Goods
    Health Care
  • Bausch + Lomb Announces Fourth-Quarter and Full-Year 2024 Results, Provides 2025 Guidance

    Fourth-Quarter 2024 Financial Results Revenue of $1.280 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $3 Million Adjusted EBITDA excluding Acquired IPR&D (non-GAAP)1 of $259 Million Revenue Grew 9% as Reported and 11% on a Constant Currency1 Basis Compared to the Fourth Quarter of 2023, with Growth Across All Segments Full-Year 2024 Financial Results Revenue of $4.791 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $317 Million Adjusted EBITDA excluding Acquired IPR&D (non-GAAP)1 of $878 Million Revenue Grew 16% as Reported and 17% on a Constant Currency1 Basis Compared to the Full Year of 2023, with Growth Across All Segments Baus

    $BLCO
    Ophthalmic Goods
    Health Care
  • Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2024 Financial Results on February 19

    Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its fourth-quarter and full-year 2024 financial results on Wednesday, February 19, 2025. Bausch + Lomb will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of the call. Conference Call Details Date: Wednesday, February 19, 2025 Time: 8 a.m. ET Webcast: https://www.webcaster4.com/Webcast/Page/2883/51712 Partici

    $BLCO
    Ophthalmic Goods
    Health Care

$BLCO
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more